Cellectis SA (NASDAQ:CLLS) – Stock analysts at Oppenheimer upped their FY2019 earnings per share (EPS) estimates for Cellectis in a research note issued to investors on Wednesday, August 21st, Zacks Investment Research reports. Oppenheimer analyst H. Singh now anticipates that the biotechnology company will post earnings per share of ($2.71) for the year, up from their previous estimate of ($2.77). Oppenheimer also issued estimates for Cellectis’ Q4 2019 earnings at ($0.63) EPS, FY2020 earnings at ($2.90) EPS, FY2021 earnings at ($3.12) EPS, FY2022 earnings at ($3.21) EPS and FY2023 earnings at ($0.59) EPS.
Several other equities research analysts have also recently weighed in on the stock. Goldman Sachs Group set a $20.00 price objective on shares of Cellectis and gave the stock a “hold” rating in a research report on Monday, August 12th. ValuEngine raised shares of Cellectis from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. BidaskClub cut shares of Cellectis from a “sell” rating to a “strong sell” rating in a report on Saturday, August 17th. Zacks Investment Research raised shares of Cellectis from a “sell” rating to a “hold” rating in a report on Monday, August 26th. Finally, Citigroup reissued a “neutral” rating and issued a $22.00 target price on shares of Cellectis in a report on Friday, May 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $31.67.
CLLS traded down $0.42 on Monday, hitting $11.86. 66,500 shares of the stock were exchanged, compared to its average volume of 119,862. Cellectis has a 12 month low of $11.53 and a 12 month high of $29.40. The business has a 50-day moving average of $12.76 and a two-hundred day moving average of $16.38. The company has a debt-to-equity ratio of 0.11, a current ratio of 8.47 and a quick ratio of 8.46. The firm has a market capitalization of $501.76 million, a price-to-earnings ratio of -6.15 and a beta of 1.76.
Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.18). Cellectis had a negative net margin of 813.06% and a negative return on equity of 21.51%. The business had revenue of $2.93 million during the quarter, compared to analyst estimates of $3.45 million.
Hedge funds have recently bought and sold shares of the company. Nikko Asset Management Americas Inc. raised its holdings in Cellectis by 48.9% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,224,334 shares of the biotechnology company’s stock valued at $19,100,000 after buying an additional 401,888 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its position in Cellectis by 48.1% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,210,019 shares of the biotechnology company’s stock valued at $18,876,000 after purchasing an additional 392,841 shares during the period. ARK Investment Management LLC increased its position in Cellectis by 18.1% during the 2nd quarter. ARK Investment Management LLC now owns 1,103,186 shares of the biotechnology company’s stock valued at $17,210,000 after purchasing an additional 169,110 shares during the period. Morgan Stanley increased its position in Cellectis by 56.6% during the 2nd quarter. Morgan Stanley now owns 494,775 shares of the biotechnology company’s stock valued at $7,719,000 after purchasing an additional 178,865 shares during the period. Finally, Point72 Asset Management L.P. increased its position in Cellectis by 66.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 142,500 shares of the biotechnology company’s stock valued at $2,223,000 after purchasing an additional 57,100 shares during the period. 32.30% of the stock is owned by hedge funds and other institutional investors.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.